Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

ClinicalTrials.gov ID

NCT06263387

Lead Sponsor

French Innovative Leukemia OrganisationOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

230Estimated

Last Update Posted

Jul 23, 2024Actual

Start Date

Jul 4, 2024Actual

Primary Completion Date

Dec 31, 2024Estimated

Completion Date

Mar 30, 2025Estimated

Official Title

Results From a Nationwide Cohort Temporary Utilization Authorization (ATU) of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC),Treated in France With Venetoclax Azacitidine

Brief Summary

Following the results of the phase 1b and the phase 3 studies, Venetoclax/Azacitidine (VEN/AZA) was available in France for newly diagnosed AML patients ineligible-IC patients through the early access program the so-called ATU program.

Venetoclax (VEN) has been available in France through the ATU since Feb 2021 and through the current post-ATU schema from the point of marketing authorization approval and up to the pending publication of reimbursement and price. Between February 15, 2021, and June 30, 2021, 285 requests for ATU were made to the pharmaceutical company (Abbvie) and led to the initiation of treatment of more than 230 patients. At the end of ATU period, all these 230 ATU patients continued to be treated by VEN/AZA as part of the current post-ATU period. Healthcare professionals and health care decision makers need real world data to better understand the benefit/risk profile of treatment. Early access to treatment in France is close to real-life setting condition.

• AML, Adult

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Adult patients
• treatment with VEN-AZA for newly diagnosed AML and ineligible to intensive chemotherapy
• Treatment in the named-patients program (ATU)

Exclusion Criteria:

• Treatment with VEN-AZA for previously treated AML

  • Prior treatment for preexisting hematological malignancies other that AML, including AZA is not an exclusion criteria
  • HYDROXYCARBAMIDE given for AML is not an exclusion criteria
  • AZA started before VEN for AML is not an exclusion criteria

• Opposition to data collection

Observational Model

Cohort

Time Perspective

Cross-Sectional

Lead Sponsor

French Innovative Leukemia OrganisationOTHER

Collaborators

Acute Leukemia French AssociationOTHER

mahunault@chu-angers.fr

chebrek.safia@ch-avignon.fr

abanos@ch-cotebasque.fr

ydesbrosses@chu-besancon.fr

gaelle.guillerm@chu-brest.fr

chantepie-s@chu-caen.fr

ioana.vaida@ght-novo.fr

pierre.arnautou@intradef.gouv.fr

gaspasrequena@chu-clermontferrand.fr

cecile.pautas@aphp.fr

marie-lorraine.chretien@chu-dijon.fr

MCarre1@chu-grenoble.fr

klaribi@ch-lemans.fr

celine.berthon@chu-lille.fr

pascal.turlure@chu-limoges.fr

mael.heiblig@chu-lyon.fr

GARCIAZS@ipc.unicancer.fr

jfrayfer@ghef.fr

h.debarri@chr-metz-thionville.fr

l-gabellier@chu-montpellier.fr

pierre.peterlin@chu-nantes.fr

cluzeau.t@chu-nice.fr

eric.jourdan@chu-nimes.fr

madalina.uzunov@psl.aphp.fr

ambroise.marcais@aphp.fr

emmanuel.raffoux@aphp.fr

pierre-yves.dumas@chu-bordeaux.fr

chimberlin@chu-reims.fr

tony.marchand@chu-rennes.fr

mathieu.wemeau@ch-roubaix.fr

r.garidi@ch-stquentin.fr

a.villate@chu-tours.fr

alberto.santagostino@ch-troyes.fr

c.bonmati@chu-nancy.fr

jlambert@ch-versailles.fr

florence.pasquier@gustaveroussy.fr

• Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory

  NCT06429670

  CompletedObservationalUpdated May 28, 2024
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets

  NCT05215639

  CompletedObservationalUpdated Dec 10, 2025
• A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy

  NCT06058741

  Active, not recruitingObservationalUpdated Apr 22, 2025
• Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

  NCT07478991

  RecruitingInterventionalPhase 3Updated Aug 31, 2026
• Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven

  NCT06030089

  CompletedInterventionalNot ApplicableUpdated Dec 16, 2025
• A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

  NCT02993523

  Active, not recruitingInterventionalPhase 3Updated Jun 11, 2026